SuleimanAlfredMassarwehMD

Breast Cancer

Medical Oncologist, Breast Cancer Specialist.

Dr. Massarweh is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

I am a medical oncologist and clinician investigator specialized in breast cancer, with a particular focus in hormone receptor positive disease, triple positive breast cancer and breast cancer in men. I have a strong commitment to multidisciplinary and cross functional team development as well as educational leadership as integral parts of my career philosophy.

As part of my philosophy, patient centeredness must the primary driver of value in any healthcare system and the business of medicine must not be given priority over patient well being. Within this concept and as we step outside the box of current healthcare systems, physicians have a responsibility to take more leadership roles in order to restore the core values of the Medical Profession, rather than remain solely as providers or programmatic developers.

Stanford Graduate School of BusinessLEAD Program in Corporate Innovation, LEAD Certificate, 2016 - 2018
Baylor College of MedicineFellowship, Hematology and Medical Oncology, 1999 - 2003
Baylor College of MedicineResidency, Internal Medicine, 1996 - 1999
University of Jordan Faculty of MedicineClass of 1994

Intellectual Contribution Award-Crisis Management Stanford Graduate School of Business-LEAD Program in Corporate Innovation, 2020
Stanford GSB LEAD Certificate Stanford Graduate School of Business, 2018
The Saul A. Rosenberg Faculty Teaching Award Stanford Medicine, 2018
National Liklihood To Recommend (LTR) Scores above 90th Percentile 2018
Intellectual Contribution Award-Business Model Analysis and Design Stanford Graduate School of Business-Lead Program in Corporate Innovation, 2017
Merit Award American Society of Clinical Oncology (ASCO), 2002-2003
Join now to see all

PubMed

119 citations
Mechanisms of tumor regression and resistance to estrogen deprivation and fulvestrant in a model of estrogen receptor-positive, HER-2/neu-positive breast cancer.
Suleiman Massarweh, C. Kent Osborne, Shou Jiang, Alan E. Wakeling, Mothaffar F. Rimawi
Cancer Research. 2006-08-15
47 citations
Molecular Characterization and Mortality From Breast Cancer in Men.
Suleiman Massarweh, George W. Sledge, Dave P. Miller, Debbie McCullough, Valentina I. Petkov
Journal of Clinical Oncology. 2018-03-27
889 citations
Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer.
Jiang Shou, Suleiman Massarweh, C. Kent Osborne, A. E. Wakeling, Simale Ali
Journal of the National Cancer Institute. 2004-06-16

Journal Articles

Inferring breast cancer concomitant diagnosis and comorbidities from the Nationwide Inpatient Sample using social network analysis
Radhakrishnan Nagarajan, Shengfan Zhang, Fay Cobb Payton, Suleiman Massarweh, Health Systems, 3/7/2014
The Role of Ovarian Suppression in the Adjuvant Therapy of Premenopausal Women With ER-Positive Breast Cancer: A Commentary on the EBCTCG Overview Analysis
James Morgan, MD; Suleiman Massarweh, MD, The American Journal of Hematology/Oncology, 10/2007

Chair, Cancer Education, Division of Oncology, Stanford University School of Medicine 2015 - 2017

Stanford CAP Profilehttps://med.stanford.edu/profiles/suleiman-massarweh
Stanford Healthcarehttps://stanfordhealthcare.org/doctors/m/suleiman-massarweh.html